The FDA approval of Iovance Biotherapeutics' novel cancer therapies represents a critical regulatory milestone that could significantly impact the company's stock price in the short term. The announcement and subsequent discussion in the conference call are likely to generate positive investor sentiment, as FDA approvals are pivotal for biotech companies in bringing their products to market.